Atiprimod

From WikiProjectMed
Jump to navigation Jump to search
Atiprimod
Atiprimod.svg
Ball-and-stick model of the atiprimod molecule
Clinical data
ATC code
  • none
Identifiers
  • 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N- diethylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H44N2
Molar mass336.608 g·mol−1
3D model (JSmol)
  • N(CC)(CC)CCCN2CCC1(CCC(CC1)(CCC)CCC)C2
  • InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3 checkY
  • Key:SERHTTSLBVGRBY-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Atiprimod (INN, codenamed SK&F106615) is a substance being studied in the treatment of certain multiple myelomas and other advanced cancers. It may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. This drug is also being researched as a potential treatment for various autoimmune diseases. It was first developed by GlaxoSmithKline as a potential treatment for rheumatoid arthritis.[1] The substance is also known as azaspirane, although this more properly refers to the class of chemicals to which atiprimod belongs.

This compound has also been shown to kill mantle cell lymphoma cells in vitro.[2]

Mechanism of action

Atiprimod has been shown to inhibit angiogenesis (growth of blood vessels) in a blood vessel model using chicken eggs. It is thought to inhibit the secretion of vascular endothelial growth factor (VEGF), a growth factor that promotes angiogenesis.

Chemistry

Atiprimod is an amphiphilic compound and a cation at neutral pH.

Synthesis

Atiprimod synthesis: Anormed Inc. Dagger, R. E.; Grady, C. W.; 1999, U.S. Patent 5,952,365.

References

  1. ^ Jacobs GS (Spring 2004). "Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma". Myeloma Today. International Myeloma Foundation. 5 (10). Archived from the original on 2011-07-18. Retrieved 2010-09-30.
  2. ^ Wang, M.; Zhang, L.; Han, X.; Yang, J.; Qian, J.; Hong, S.; Samaniego, F.; Romaguera, J.; Yi, Q. (2007). "Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways". Blood. 109 (12): 5455–5462. doi:10.1182/blood-2006-12-063958. PMID 17317853.

Further reading

External links

  • Atiprimod entry in the public domain NCI Dictionary of Cancer Terms

Public Domain This article incorporates public domain material from the U.S. National Cancer Institute document: "Dictionary of Cancer Terms".